Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study

(2020) Jeffrey D McCurdy et al.   INFLAMMATORY BOWEL DISEASES

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

(2020) Jun K Khoo et al.   RHEUMATOLOGY

Venous thromboembolism in inflammatory bowel disease

(2020) Kimberly Cheng et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

(2020) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk

(2020) Suraj Rajasimhan et al.   DRUGS & AGING

Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases

(2020) Esther Benamu   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Cardiovascular Risk Factors Associated With Venous Thromboembolism

(2019) John Gregson et al.   JAMA Cardiology

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

(2019) Wenhui Xie et al.   ANNALS OF THE RHEUMATIC DISEASES

Myocardial Infarction as a Transient Risk Factor for Incident Venous Thromboembolism: Results from a Population-Based Case–Crossover Study

(2019) Joakim K. Sejrup et al.   THROMBOSIS AND HAEMOSTASIS

JAK inhibitors for the treatment of autoimmune and inflammatory diseases

(2019) Yvan Jamilloux et al.   AUTOIMMUNITY REVIEWS

Risk of Recurrent Venous Thromboembolism in Autoimmune Diseases: A Systematic Review of the Literature

(2018) Karina Leeuw et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

(2018) Josef S. Smolen et al.   JOURNAL OF RHEUMATOLOGY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis

(2017) Joel M. Kremer et al.   Arthritis & Rheumatology

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines

(2016) Silvio Danese et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs

(2016) Scott D. Grosse et al.   THROMBOSIS RESEARCH

Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2014) Patompong Ungprasert et al.   CLINICAL RHEUMATOLOGY

Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study

(2013) Wei-Sheng Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE